| Date Filed | Type | Description |
| 10/13/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/10/2023 |
SC 13G
| Cormorant Asset Management, LP reports a 5.5% stake in Marinus Pharmaceuticals, Inc. |
| 04/24/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 03/13/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 17.7% stake in Ambrx Biopharma Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.4% stake in Elevation Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 9.2% stake in Design Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.1% stake in GreenLight Biosciences Holdings, PBC |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8.7% stake in Immuneering Corporation |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Ambrx Biopharma Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6% stake in Monte Rosa Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in BioAtla, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 8% stake in Aerovate Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.8% stake in Cabaletta Bio, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.7% stake in Arcellx, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.2% stake in Olema Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 5.3% stake in Altimmune, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 2.7% stake in Viridian Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Longboard Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.5% stake in Tarsus Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 6.3% stake in Astria Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4% stake in VectivBio Holding AG |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.7% stake in Tango Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 4.5% stake in Prometheus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| Cormorant Asset Management, LP reports a 10% stake in Eledon Pharmaceuticals, Inc. |
| 12/29/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/27/2022 |
SC 13G
| Cormorant Asset Management, LP reports a 5.1% stake in Avidity Biosciences, Inc. |
| 12/21/2022 |
SC 13D/A
| Cormorant Asset Management, LP reports a 7.3% stake in Erasca, Inc. |
| 10/31/2022 |
SC 13G
| Cormorant Asset Management, LP reports a 7.8% stake in Cabaletta Bio, Inc. |
| 09/02/2022 |
SC 13G
| Cormorant Asset Management, LP reports a 5.4% stake in Astria Therapeutics, Inc. |
| 08/29/2022 |
SC 13G
| Cormorant Asset Management, LP reports a 5% stake in Arcellx, Inc. |
| 07/07/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/17/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/06/2022 |
SC 13G
| Cormorant Asset Management, LP reports a 5.7% stake in Prometheus Biosciences, Inc. |
| 02/14/2022 |
SC 13G
| Cormorant Asset Management, LP reports a 7.7% stake in GreenLight Biosciences Holdings, PBC |
|